儿童大环内酯类耐药肺炎支原体肺炎抗菌药物治疗的研究进展
Research Progress of Antibacterial Therapy of Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Children
DOI: 10.12677/acm.2025.154897, PDF,   
作者: 刘 杨, 谢晓虹*：重庆医科大学附属儿童医院呼吸科，儿童发育疾病研究教育部重点实验室，国家儿童健康与疾病临床医学研究中心，儿童发育重大疾病国家国际科技合作基地，儿科学重庆市重点实验室，重庆
关键词: 肺炎支原体；大环内酯类耐药；氟喹诺酮类；四环素类；Mycoplasma pneumoniae； Macrolide Resistance； Fluoroquinolones； Tetracyclines
摘要: 肺炎支原体(Mycoplasma pneumoniae, MP)是社区获得性肺炎(Community-acquired pneumonia, CAP)的常见病原体之一，常引起全球范围内感染，每4~7年可爆发地区流行。重症MP感染有生命危险，并且部分可遗留闭塞性支气管炎等后遗症。由于MP缺乏细胞壁，不同国家常将大环内酯类抗菌药物作为首选治疗肺炎支原体肺炎(Mycoplasma pneumoniae pneumonia, MPP)的药物。但自2000年以来，大环内酯类耐药肺炎支原体肺炎(Macrolide-resistant Mycoplasma pneumoniae, MRMP)在全球不同国家和地区的耐药率逐年上升，尤其是东亚地区，这对儿童健康带来极大威胁，对公共卫生健康带来极大挑战。
Abstract: Mycoplasma pneumoniae is one of the common pathogens of community-acquired pneumonia, which often causes worldwide infection, and can be prevalent in areas every 4~7 years. Severe MP infection is life-threatening, and some may leave sequelae such as bronchitis obliterans. Due to the lack of cell wall in MP, macrolide antibacterial drugs are often used as the first choice for the treatment of Mycoplasma pneumoniae pneumonia in different countries. However, since 2000, the drug resistance rate of macrolide-resistant Mycoplasma pneumoniae pneumonia has increased year by year in different countries and regions around the world, especially in East Asia, which poses a great threat to children’s health and a great challenge to public health.
文章引用：刘杨, 谢晓虹. 儿童大环内酯类耐药肺炎支原体肺炎抗菌药物治疗的研究进展[J]. 临床医学进展, 2025, 15(4): 17-26. https://doi.org/10.12677/acm.2025.154897

参考文献

[1] Xiao, L., Ptacek, T., Osborne, J.D., Crabb, D.M., Simmons, W.L., Lefkowitz, E.J., et al. (2015) Comparative Genome Analysis of Mycoplasma pneumoniae. BMC Genomics, 16, Article No. 610. [Google Scholar] [CrossRef] [PubMed]
[2] Xu, M.X., Li, Y., Shi, Y., Liu, H.Z., Tong, X., Ma, L., et al. (2024) Molecular Epidemiology of Mycoplasma pneumoniae Pneumonia in Children, Wuhan, 2020-2022. BMC Microbiology, 24, Article No. 23. [Google Scholar] [CrossRef] [PubMed]
[3] Ou, G., Liu, Y., Tang, Y., et al. (2015) In Vitro Subminimum Inhibitory Concentrations of Macrolide Antibiotics Induce Macrolide Resistance in Mycoplasma pneumoniae. Hippokratia, 19, 57-62.
[4] Morozumi, M., Ubukata, K. and Takahashi, T. (2010) Macrolide-Resistant Mycoplasma pneumoniae: Characteristics of Isolates and Clinical Aspects of Community-Acquired Pneumonia. Journal of Infection and Chemotherapy, 16, 78-86. [Google Scholar] [CrossRef] [PubMed]
[5] Ando, M., Morozumi, M., Adachi, Y., Ubukata, K. and Iwata, S. (2018) Multilocus Sequence Typing of Mycoplasma pneumoniae, Japan, 2002-2016. Emerging Infectious Diseases, 24, 1895-1901. [Google Scholar] [CrossRef] [PubMed]
[6] Suzuki, Y., Seto, J., Shimotai, Y., Ikeda, T., Yahagi, K., Mizuta, K., et al. (2016) Development of an Endpoint Genotyping Assay to Detect the Mycoplasma pneumoniae 23S rRNA Gene and Distinguish the Existence of Macrolide Resistance-Associated Mutations at Position 2063. Journal of Microbiological Methods, 131, 130-134. [Google Scholar] [CrossRef] [PubMed]
[7] Zhao, F., Li, J., Liu, J.R., Guan, X.M., Gong, J., Liu, L.Y., et al. (2019) Antimicrobial Susceptibility and Molecular Characteristics of Mycoplasma pneumoniae Isolates across Different Regions of China. Antimicrobial Resistance & Infection Control, 8, Article No. 143. [Google Scholar] [CrossRef] [PubMed]
[8] Zaman, S., Fitzpatrick, M., Lindahl, L. and Zengel, J. (2007) Novel Mutations in Ribosomal Proteins L4 and L22 That Confer Erythromycin Resistance in Escherichia coli. Molecular Microbiology, 66, 1039-1050. [Google Scholar] [CrossRef] [PubMed]
[9] Pereyre, S., Guyot, C., Renaudin, H., Charron, A., Bébéar, C. and Bébéar, C.M. (2004) In Vitro Selection and Characterization of Resistance to Macrolides and Related Antibiotics in Mycoplasma pneumoniae. Antimicrobial Agents and Chemotherapy, 48, 460-465. [Google Scholar] [CrossRef] [PubMed]
[10] Liu, X.J., Jiang, Y., Chen, X.G., Li, J., Shi, D.W. and Xin, D.L. (2014) Drug Resistance Mechanisms of Mycoplasma pneumoniae to Macrolide Antibiotics. BioMed Research International, 2014, Article 320801. [Google Scholar] [CrossRef] [PubMed]
[11] Li, S.L., Xue, G.H., Zhao, H.Q., Feng, Y.L., Yan, C., Cui, J.H., et al. (2021) Quantitative Proteomics Analysis of Mycoplasma pneumoniae Identifies Potential Macrolide Resistance Determinants. AMB Express, 11, Article No. 26. [Google Scholar] [CrossRef] [PubMed]
[12] Okazaki, N., Narita, M., Yamada, S., Izumikawa, K., Umetsu, M., Kenri, T., et al. (2001) Characteristics of Macrolide‐resistant mycoplasma pneumoniae Strains Isolated from Patients and Induced with Erythromycin in Vitro. Microbiology and Immunology, 45, 617-620. [Google Scholar] [CrossRef] [PubMed]
[13] Meyer Sauteur, P.M., Beeton, M.L., et al. (2024) Mycoplasma pneumoniae: Delayed Re-Emergence after COVID-19 Pandemic Restrictions. The Lancet, 5, e100-e101.
[14] Wang, X., Li, M.Z., Luo, M., Luo, Q., Kang, L., Xie, H., et al. (2022) Mycoplasma pneumoniae Triggers Pneumonia Epidemic in Autumn and Winter in Beijing: A Multicentre, Population-Based Epidemiological Study between 2015 and 2020. Emerging Microbes & Infections, 11, 1508-1517. [Google Scholar] [CrossRef] [PubMed]
[15] Cheng, Y.A., Cheng, Y.J., Dai, S.Z., Hou, D.Q., Ge, M.L., Zhang, Y., et al. (2022) The Prevalence of Mycoplasma pneumoniae among Children in Beijing before and during the COVID-19 Pandemic. Frontiers in Cellular and Infection Microbiology, 12, Article 854505. [Google Scholar] [CrossRef] [PubMed]
[16] Wu, H.-M., Wong, K.-S., Huang, Y.-C., Lai, S.-H., Tsao, K.-C., Lin, Y.-J., et al. (2013) Journal of Infection and Chemotherapy, 19, 782-786. [Google Scholar] [CrossRef] [PubMed]
[17] Mao, J.B., Chen, D.N., Lu, W.B., et al. (2024) Epidemiological Characteristics of Mycoplasma pneumoniae Infection and Drug Resistance Gene Mutation in Hospitalized Children Aged 0-17 Years in Ningbo City from 2019 to 2023. Chinese Journal of Preventive Medicine, 58, 1035-1040.
[18] You, J.Y., Zhang, L.H., Chen, W., Wu, Q.F., Zhang, D.Y., Luo, Z.X., et al. (2024) Epidemiological Characteristics of Mycoplasma pneumoniae in Hospitalized Children Before, During, and after COVID-19 Pandemic Restrictions in Chongqing, China. Frontiers in Cellular and Infection Microbiology, 14, Article 1424554. [Google Scholar] [CrossRef] [PubMed]
[19] Wu, T.-H., Fang, Y.-P., Liu, F.-C., Pan, H.-H., Yang, Y.-Y., Song, C.-S., et al. (2024) Emerging Infectious Diseases, 30, 1692-1696. [Google Scholar] [CrossRef] [PubMed]
[20] Meyer Sauteur, P.M., Beeton, M.L., Uldum, S.A., Bossuyt, N., Vermeulen, M., Loens, K., et al. (2022) Mycoplasma pneumoniae Detections before and during the COVID-19 Pandemic: Results of a Global Survey, 2017 to 2021. Eurosurveillance, 27, Article 2100746. [Google Scholar] [CrossRef] [PubMed]
[21] Lee, J.K., Choi, Y.Y., Sohn, Y.J., Kim, K., Kim, Y.K., Han, M.S., et al. (2022) Persistent High Macrolide Resistance Rate and Increase of Macrolide-Resistant ST14 Strains among Mycoplasma pneumoniae in South Korea, 2019-2020. Journal of Microbiology, Immunology and Infection, 55, 910-916. [Google Scholar] [CrossRef] [PubMed]
[22] Lee, J.K., Lee, T., Kim, Y., Kim, D.R., Shin, A., Kang, H.M., et al. (2024) Clinical Manifestations, Macrolide Resistance, and Treatment Utilization Trends of Mycoplasma pneumoniae pneumonia in Children and Adolescents in South Korea. Microorganisms, 12, Article 1806. [Google Scholar] [CrossRef] [PubMed]
[23] Xiao, L., Ratliff, A.E., Crabb, D.M., Mixon, E., Qin, X., Selvarangan, R., et al. (2020) Molecular Characterization of Mycoplasma pneumoniae Isolates in the United States from 2012 to 2018. Journal of Clinical Microbiology, 58, e00710-20. [Google Scholar] [CrossRef] [PubMed]
[24] Rothstein, T.E., Cunningham, S.A., Rieke, R.A., Mainella, J.M., Mutchler, M.M. and Patel, R. (2022) Macrolide Resistance in Mycoplasma pneumoniae, Midwestern United States, 2014 to 2021. Antimicrobial Agents and Chemotherapy, 66, e02432-21. [Google Scholar] [CrossRef] [PubMed]
[25] (2012) LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases.
[26] Suzuki, Y., Shimotai, Y., Itagaki, T., Seto, J., Ikeda, T., Yahagi, K., et al. (2017) Development of Macrolide Resistance-Associated Mutations after Macrolide Treatment in Children Infected with Mycoplasma pneumoniae. Journal of Medical Microbiology, 66, 1531-1538. [Google Scholar] [CrossRef] [PubMed]
[27] Okazaki, N., Narita, M., Yamada, S., Izumikawa, K., Umetsu, M., Kenri, T., et al. (2001) Characteristics of Macrolide‐Resistant Mycoplasma pneumoniae Strains Isolated from Patients and Induced with Erythromycin in Vitro. Microbiology and Immunology, 45, 617-620. [Google Scholar] [CrossRef] [PubMed]
[28] Jiang, Y., Dou, H.W., Xu, B., Xu, B.P., Zhou, W., Wang, H., et al. (2024) Macrolide Resistance of Mycoplasma pneumoniaein Several Regions of China from 2013 to 2019. Epidemiology and Infection, 152, e75. [Google Scholar] [CrossRef] [PubMed]
[29] Zhao, F., Li, J., Liu, J.R., Guan, X.M., Gong, J., Liu, L.Y., et al. (2019) Antimicrobial Susceptibility and Molecular Characteristics of Mycoplasma pneumoniae Isolates across Different Regions of China. Antimicrobial Resistance & Infection Control, 8, Article No. 143. [Google Scholar] [CrossRef] [PubMed]
[30] Cheong, K., Chiu, S.S., Chan, B.W., To, K.K., Chan, E.L. and Ho, P. (2016) Severe Macrolide-Resistant Mycoplasma pneumoniae Pneumonia Associated with Macrolide Failure. Journal of Microbiology, Immunology and Infection, 49, 127-130. [Google Scholar] [CrossRef] [PubMed]
[31] Yoon, I.A., Hong, K.B., Lee, H.J., Yun, K.W., Park, J.Y., Choi, Y.H., et al. (2017) Radiologic Findings as a Determinant and No Effect of Macrolide Resistance on Clinical Course of Mycoplasma pneumoniae Pneumonia. BMC Infectious Diseases, 17, Article No. 402. [Google Scholar] [CrossRef] [PubMed]
[32] Matsubara, K., Okada, T., Matsushima, T., Komiyama, O., Iwata, S., Morozumi, M., et al. (2009) A Comparative Clinical Study of Macrolide-Sensitive and Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Patients. Journal of Infection and Chemotherapy, 15, 380-383. [Google Scholar] [CrossRef] [PubMed]
[33] 林江涛, 张永明, 周新, 等. 大环内酯类药物的抗菌外作用与临床应用专家共识[J]. 中华内科杂志, 2017, 56(7), 546-557.
[34] Principi, N. and Esposito, S. (2012) Macrolide-Resistant Mycoplasma pneumoniae: Its Role in Respiratory Infection. Journal of Antimicrobial Chemotherapy, 68, 506-511. [Google Scholar] [CrossRef] [PubMed]
[35] Cao, B., Zhao, C.-J., Yin, Y.-D., Zhao, F., Song, S.-F., Bai, L., et al. (2010) High Prevalence of Macrolide Resistance in Mycoplasma pneumoniae Isolates from Adult and Adolescent Patients with Respiratory Tract Infection in China. Clinical Infectious Diseases, 51, 189-194. [Google Scholar] [CrossRef] [PubMed]
[36] Yin, Y.-D., Cao, B., Wang, H., et al. (2013) Survey of Macrolide Resistance in Mycoplasma pneumoniae in Adult Patients with Community-Acquired Pneumonia in Beijing, China. Chinese Journal of Tuberculosis and Respiratory Diseases, 36, 1-5.
[37] Kawai, Y., Miyashita, N., Kubo, M., Akaike, H., Kato, A., Nishizawa, Y., et al. (2013) Therapeutic Efficacy of Macrolides, Minocycline, and Tosufloxacin against Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Pediatric Patients. Antimicrobial Agents and Chemotherapy, 57, 2252-2258. [Google Scholar] [CrossRef] [PubMed]
[38] Miyashita, N., Akaike, H., Teranishi, H., Ouchi, K. and Okimoto, N. (2013) Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Adolescents and Adults: Clinical Findings, Drug Susceptibility, and Therapeutic Efficacy. Antimicrobial Agents and Chemotherapy, 57, 5181-5185. [Google Scholar] [CrossRef] [PubMed]
[39] Yamazaki, T., Sasaki, T. and Takahata, M. (2007) Activity of Garenoxacin against Macrolide-Susceptible and-Resistant Mycoplasma pneumoniae. Antimicrobial Agents and Chemotherapy, 51, 2278-2279. [Google Scholar] [CrossRef] [PubMed]
[40] Waites, K.B., Crabb, D.M. and Duffy, L.B. (2008) Comparative in Vitro Activities of the Investigational Fluoroquinolone DC-159a and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrobial Agents and Chemotherapy, 52, 3776-3778. [Google Scholar] [CrossRef] [PubMed]
[41] Cardinale, F., Chironna, M., Dumke, R., Binetti, A., Daleno, C., Sallustio, A., et al. (2011) Macrolide-Resistant Mycoplasma pneumoniaein Paediatric Pneumonia. European Respiratory Journal, 37, 1522-1524. [Google Scholar] [CrossRef] [PubMed]
[42] Hantz, S., Garnier, F., Peuchant, O., Menetrey, C., Charron, A., Ploy, M., et al. (2012) Multilocus Variable-Number Tandem-Repeat Analysis-Confirmed Emergence of a Macrolide Resistance-Associated Mutation in Mycoplasma pneumoniae during Macrolide Therapy for Interstitial Pneumonia in an Immunocompromised Child. Journal of Clinical Microbiology, 50, 3402-3405. [Google Scholar] [CrossRef] [PubMed]
[43] Ahn, J.G., Cho, H., Li, D., Choi, M., Lee, J., Eun, B., et al. (2021) Efficacy of Tetracyclines and Fluoroquinolones for the Treatment of Macrolide-Refractory Mycoplasma pneumoniae Pneumonia in Children: A Systematic Review and Meta-Analysis. BMC Infectious Diseases, 21, Article No. 1003. [Google Scholar] [CrossRef] [PubMed]
[44] Cardinale, F., Chironna, M., Chinellato, I., Principi, N. and Esposito, S. (2013) Clinical Relevance of Mycoplasma pneumoniae Macrolide Resistance in Children. Journal of Clinical Microbiology, 51, 723-724. [Google Scholar] [CrossRef] [PubMed]
[45] The subspecialty Group of Respiratory Disease, the SOCIETY of Pediatrics, Chinese Medical Association, The Editorial Board, Chinese Journal of Pediatrics (2013) Guidelines for Management of Community Acquired Pneumonia in Children (The Revised Edition of 2013). Chinese Journal of Pediatrics, 51, 745-799.
[46] He, Y.-S., Yang, M., Liu, G., Ji, J. and Qian, S.-Y. (2023) Safety Study of Moxifloxacin in Children with Severe Refractory Mycoplasma pneumoniae Pneumonia. Pediatric Pulmonology, 58, 2017-2024. [Google Scholar] [CrossRef] [PubMed]
[47] Kim, Y., Park, G.W., Kim, S., Moon, H.J., Won, S., Chung, W., et al. (2021) Fluoroquinolone and No Risk of Achilles-Tendinopathy in Childhood Pneumonia under Eight Years of Age—A Nationwide Retrospective Cohort. Journal of Thoracic Disease, 13, 3399-3408. [Google Scholar] [CrossRef] [PubMed]
[48] Noel, G.J., Bradley, J.S., Kauffman, R.E., Duffy, C.M., Gerbino, P.G., Arguedas, A., et al. (2007) Comparative Safety Profile of Levofloxacin in 2523 Children with a Focus on Four Specific Musculoskeletal Disorders. Pediatric Infectious Disease Journal, 26, 879-891. [Google Scholar] [CrossRef] [PubMed]
[49] Zhao, F., Li, J., Liu, J.R., Guan, X.M., Gong, J., Liu, L., et al. (2019) Antimicrobial Susceptibility and Molecular Characteristics of Mycoplasma pneumoniae Isolates across Different Regions of China. Antimicrobial Resistance & Infection Control, 8, Article No. 143. [Google Scholar] [CrossRef] [PubMed]
[50] Carris, N.W., Pardo, J., Montero, J. and Shaeer, K.M. (2015) Minocycline as a Substitute for Doxycycline in Targeted Scenarios: A Systematic Review. Open Forum Infectious Diseases, 2, ofv178. [Google Scholar] [CrossRef] [PubMed]
[51] Cao, B., Qu, J.-X., Yin, Y.-D. and Van Eldere, J. (2015) Overview of Antimicrobial Options for Mycoplasma pneumoniae Pneumonia: Focus on Macrolide Resistance. The Clinical Respiratory Journal, 11, 419-429. [Google Scholar] [CrossRef] [PubMed]
[52] Oishi, T., Takahashi, K., Wakabayashi, S., Nakamura, Y., Ono, S., Kono, M., et al. (2019) Comparing Antimicrobial Susceptibilities among Mycoplasma pneumoniae Isolates from Pediatric Patients in Japan between Two Recent Epidemic Periods. Antimicrobial Agents and Chemotherapy, 63, e02517-18. [Google Scholar] [CrossRef] [PubMed]
[53] Wang, N., Zhang, H., Yin, Y., Xu, X., Xiao, L. and Liu, Y. (2022) Antimicrobial Susceptibility Profiles and Genetic Characteristics of Mycoplasma pneumoniae in Shanghai, China, from 2017 to 2019. Infection and Drug Resistance, 15, 4443-4452. [Google Scholar] [CrossRef] [PubMed]
[54] Chen, Y., Zhang, Y., Tang, Q.-N. and Shi, H. (2024) Efficacy of Doxycycline Therapy for Macrolide-Resistant Mycoplasma pneumoniae Pneumonia in Children at Different Periods. Italian Journal of Pediatrics, 50, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[55] Cai, F.Q., Li, J.L., Liang, W.J., Wang, L. and Ruan, J.S. (2024) Effectiveness and Safety of Tetracyclines and Quinolones in People with Mycoplasma pneumonia: A Systematic Review and Network Meta-Analysis. eClinicalMedicine, 71, Article 102589. [Google Scholar] [CrossRef] [PubMed]
[56] Morozumi, M., Okada, T., Tajima, T., Ubukata, K. and Iwata, S. (2017) Killing Kinetics of Minocycline, Doxycycline and Tosufloxacin against Macrolide-Resistant Mycoplasma pneumoniae. International Journal of Antimicrobial Agents, 50, 255-257. [Google Scholar] [CrossRef] [PubMed]
[57] Chopra, I. and Roberts, M. (2001) Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance. Microbiology and Molecular Biology Reviews, 65, 232-260. [Google Scholar] [CrossRef] [PubMed]
[58] Todd, S.R., Dahlgren, F.S., Traeger, M.S., Beltrán-Aguilar, E.D., Marianos, D.W., Hamilton, C., et al. (2015) No Visible Dental Staining in Children Treated with Doxycycline for Suspected Rocky Mountain Spotted Fever. The Journal of Pediatrics, 166, 1246-1251. [Google Scholar] [CrossRef] [PubMed]
[59] Editing Group for Multidisciplinary Expert Consensus on the Rational Use of Tetracyclines Commonly Used in Clinical Practice, Hospital Infection Control Branch of Chinese Preventive Medicine Association, Clinical Pharmacology Branch of Chinese Pharmacological Society (2023) Multidisciplinary Expert Consensus on the Rational Use of Tetracyclines Commonly Used in Clinical Practice. Chinese Medical Journal, 103, 2281-2296.
[60] 叶军. 阿奇霉素序贯疗法对支原体肺炎患儿炎性因子及体液免疫功能的影响[J]. 中国基层医药, 2015(21), 3286-3288.

为你推荐